Advances in BTK Inhibitor Therapy for B Cell Lymphomas

CE / CME

Advances in BTK Inhibitor Therapy for B-Cell Lymphomas: Expert Discussion and Resources to Elevate Patient Care

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: December 11, 2024

Expiration: June 10, 2025

Emily Patterson
Emily Patterson, AGACNP-BC

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following BTK inhibitor is currently approved in combination with obinutuzumab in patients with relapsed or refractory FL after at least 2 previous systemic therapies?

2.

Patient Case 2: 61-Yr-Old Woman With Lymphadenopathy and LUQ pain



  • Patient: 61-yr-old woman with lymphadenopathy and LUQ pain

  • MCL, diffuse variant

  • Ki-67 = 20%

  • TP53 mutation negative

  • Primary therapy: CIT followed by ASCT + rituximab maintenance

    • Relapsed 3 yr later with liver metastases



  • Currently on: zanubrutinib

    • Now experiencing bruising and bleeding (grade 3) 6 mo after starting treatment



Which of the following is the optimal option for this patient experiencing grade 3 bleeding while on a BTK inhibitor?

3.

Rate your confidence in applying current evidence and expert recommendations to maintain patient adherence and persistence to prescribed BTK inhibitors in patients with
B-cell lymphomas?